Inclusion criteria: A Phase ½ Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor . Activity of TNG462 as a Single Agent and in Combination (with pembrolizumab) in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors.
- Confirmed histologic or cytologic diagnosis of a locally advanced, metastatic, and/or unresectable solid tumor
- Prior standard therapy, as available
- Documented bi-allelic (homozygous) deletion of MTAP in a tumor detected by next- generation sequencing or absence of MTAP protein in a tumor detected by IHC.
Sponsor/Collaborator: Tango Therapeutics, Inc.
Contact and Locations:
Name: Tango Clinical Trials
Phone Number: (857) 320-4899
Email: clinicaltrials@tangotx.com
25 Locations (U.S. and Europe): https://www.clinicaltrials.gov/study/NCT05732831#participation-criteria
Mechanism of action: TNG462, is a selective PRMT5 inhibitor administered orally.
Phases: Phase 1, Phase 2
NCT Number: NCT05732831
Status: Recruiting
